Search
Searching Content indexed under Litigation, Mediation & Arbitration by Nicole Clouse ordered by Published Date Descending.
Links to Result pages
 
1  
 
Title
Country
Organisation
Author
Date
1
Post-Priority References Can Be Used In Context Of Obviousness Analysis
In two opinions by the same panel concerning the same three patents, the US Court of Appeals for the Federal Circuit relied in part on post-priority evidence ...
United States
4 Dec 2018
2
Prediction: "Plain And Ordinary Meaning" Is Not Particularly Plain Or Ordinary
The US Court of Appeals for the Federal Circuit, finding errors in claim construction, overturned a jury verdict of infringement and affirmed a district court summary judgment determination that the claims...
United States
31 Oct 2018
3
Prosecution History Disclaimer Of Claim Scope Must Be "Clear And Unambiguous" In View Of The Prosecution History As A Whole
Judge O'Malley concurred with the opinion and its reasoning, but wrote separately about a procedural issue.
United States
29 Nov 2016
4
Once Again, Genetic Diagnostic Claims Found Unpatentable Under § 101
The Federal Circuit's decision appears to be consistent with the framework and logic set forth in Mayo, Alice and the new life sciences subject matter eligibility examples issued by the US Patent and Trademark Office.
United States
27 May 2016
5
Propriety Of A Certificate Of Correction Requires Assessment Of The Teachings Of The Specification As A Whole
The patent at issue relates to novel pharmaceutical formulations of daptomycin, a prior art antibiotic originally discovered by Eli Lilly in the 1980s.
United States
30 Dec 2015
6
A Substantially Pure Isomer Is Obvious When The Completely Pure Isomer Is Known In The Art
Many prior cases have addressed whether a pure stereoisomer is obvious when the corresponding 50/50 mixture is known in the prior art.
United States
2 Dec 2015
7
Supplier To ANDA Filer Is Not Liable For Induced Infringement Until After ANDA Approval
Shire markets a branded version of L-lysine-d-amphetamine dimesylate (LDX), an amphetamine useful for treatment of attention deficit hyperactivity disorder (ADHD).
United States
2 Nov 2015
8
Supplier To ANDA Filer Is Not Liable For Induced Infringement Until After ANDA Approval
The Federal Circuit reversed the district court's finding of induced infringement on two grounds.
United States
2 Nov 2015
9
The "Totality Of The Specification" Can Override A District Court’s Factual Findings
Giving little deference to the district court's factual findings, the U.S. Court of Appeals for the Federal Circuit reversed a district court's claim construction in a long-running dispute relating to a patent ...
United States
1 May 2015
10
PTAB Rejects Attempts To Expand The Scope Of CBM Review
Jazz’s patents at issue relate to methods of controlling access to a prescription drug which is prone to being abused.
United States
2 Mar 2015
11
Disclosure Of A Single Embodiment Can Provide Sufficient Written Description
The disclosure of a single embodiment falling with the scope of the claims was sufficient to show that the inventors had possession of the invention.
United States
3 Jul 2014
Links to Result pages
 
1